by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John...
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer. Read More
